Details
Question
- What is the clinical effectiveness of universal versus high risk palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
- What is the clinical effectiveness of seasonal versus year-round palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
- What is the cost- effectiveness of universal versus high risk palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
- What is the cost-effectiveness of seasonal (~6months) versus year-round palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants
Key Message
No relevant literature was identified regarding the comparative clinical effectiveness of universal versus high-risk palivizumab or seasonal versus year-round palivizumab prophylaxis in Inuit children up to 4 years of age. Additionally, no relevant literature was identified regarding the comparative cost effectiveness of universal versus high-risk palivizumab or seasonal versus year-round palivizumab prophylaxis in Inuit children up to 4 years of age.